TD Cowen Maintains Buy on Alnylam Pharmaceuticals, Raises Price Target to $371

Benzinga · 10/21 12:48
TD Cowen analyst Ritu Baral maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Buy and raises the price target from $282 to $371.